New multiple sclerosis (MS) treatment will cut hospital time for patients by 90%
NHS England (NHSE) has announced that a new multiple sclerosis (MS) treatment will cut hospital time for patients by 90% and free up time for clinicians.
The treatment in question is the drug ocrelizumab, which is sold as Ocrevus by Roche. Around 9,000 patients already take the drug across England in its intravenous infusion form, which is a process that can take up to four hours.
NHSE will become one of the first health systems in the world, however, to offer the drug via an injection that takes only 10 minutes, after it confirmed stocks are set to be available in the coming weeks. The frequency or efficacy of treatment is not affected by taking the drug through an injection.